Qulipta, (atogepant), was first approved for preventive treatment of Episodic Migraine on September 28, 2021. Qulipta targets Calcitonin gene-related peptide ( CGRP), to regulate its role in trigeminovascular pain transmission and neurogenic inflammation. It is the second receptor antagonist to be approved for treatment of episodic migraine, specifically 15 or less migraine days per month. Pivotal clinical trials support raid onset of significant efficacy, its safety and tolerability. Migraine is a complex disease in which many sufferers experience recurrent attacks. Qulipta approval provides a broader spectrum for migraine treatment and management. Please call The Manhattan Center for Headache and Neurology to speak with one of our caring providers regarding the new advancement in treatment!
By: Jordan Shankle, PA